



Dimercaptopropane Sulfonic Acid 50 mg/mL Injectable (Dimaval®; for heavy metal poisoning)

The Issue: dimercaprol 300 mg vials have been discontinued in Canada. The BC Drug and Poison Information Centre (DPIC) has advised that select sites in each health authority should stock an alternate product for heavy metal poisoning due to lead, mercury or arsenic: **dimercaptopropane sulfonic acid 50 mg/mL X 5 mL injectable**.

Practice Implications:

- Dimercaptopropane sulfonic acid 50 mg/mL X 5 mL ampoules will be routinely stocked in the emergency departments and pharmacies at UHNBC in Prince George, Mills Memorial Hospital in Terrace, and Dawson Creek & District Hospital, to ensure access in each health service delivery area across NH.
- Dimercaptopropane is obtained via Health Canada’s **Special Access Programme**, and requires proper documentation in order for pharmacy to replace stock.
 - Clinicians must fill out the information requested on the packaging label and return to pharmacy, including patient(s) name and MRN, date used and quantity of vials used.
- There is a parenteral drug administration monograph available for this product on [OurNH](#).
- The NH Master Antidote Stocking Guidelines document has also been updated on the [Formulary Listing](#) page of OurNH.

Clinicians can call **BC DPIC** for guidance regarding dimercaptopropane sulfonic acid for cases of heavy metal poisoning: **1-800-567-8911**.

August 5, 2022 For the information of physicians, nurses, and pharmacists. PLEASE POST	Drug Shortage		For further information contact: Medication Use Management Pharmacists mumpharmacist@northernhealth.ca
	Drug Discontinuation		
	Product Change	✓	
	Best Practice		